Deep Hypoalbuminemia in Patients with Immunoglobulin Light Chain Amyloidosis: A Risk Factor for Vascular Thromboembolic Events or Only a Causal Link?

Authors

  • Burak Uz Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Adult Hematology, Turkey
  • Kadir Acar Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Adult Hematology, Turkey

DOI:

https://doi.org/10.15379/2408-9877.2016.03.02.01

Keywords:

Letter to editor

Abstract

Letter to Editor

References

Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010; 125: 490-3. http://dx.doi.org/10.1016/j.thromres.2009.12.023

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29. http://dx.doi.org/10.3322/caac.20138

Larocco A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119: 933-9. http://dx.doi.org/10.1182/blood-2011-03-344333

Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20. http://dx.doi.org/10.1200/JCO.2005.04.242

Bever KM, Masha LI, Sun F, et al. Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica 2016; 101: 86-90. http://dx.doi.org/10.3324/haematol.2015.133900

Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117: 224-30. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.716951

Li SJ, Guo JZ, Zuo K, et al. Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study. Thromb Res 2012; 130: 501-5. http://dx.doi.org/10.1016/j.thromres.2012.04.015

Eneman B, Levtchenko E, van den Heuvel B, Van Geet C, Freson K. Platelet abnormalities in nephrotic syndrome. Pediatr Nephrol. 2015 Aug 13. [Epub ahead of print]

Vaziri ND, Paule P, Toohey J, et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984; 144: 1802-3. http://dx.doi.org/10.1001/archinte.1984.00350210124021

Nishimura M, Shimada J, Ito K, Kawachi H, Nishiyama K. Acute arterial thrombosis with antithrombin III deficiency in nephrotic syndrome: report of a case. Surg Today 2000; 30: 663-6. http://dx.doi.org/10.1007/s005950070110

Halligan CS, Lacy MQ, Vincent Rajkumar S, et al. Natural history of thromboembolism in AL amyloidosis. Amyloid 2006; 13: 31-6. http://dx.doi.org/10.1080/13506120500537285

Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4: 1470-5. http://dx.doi.org/10.1111/j.1538-7836.2006.01928.x

Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 653-63. http://dx.doi.org/10.1111/j.1538-7836.2011.04215.x

Bagratuni T, Kastritis E, Politou M, et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 2013; 88: 765-70. http://dx.doi.org/10.1002/ajh.23504

Leleu X, Rodon P, Hulin C, et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost 2013; 110: 844-51. http://dx.doi.org/10.1160/TH13-02-0140

Downloads

Published

2016-07-28

Issue

Vol. 3 No. 2 (2016)

Section

Articles

License

Policy for Journals/Articles with Open Access

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work

Policy for Journals / Manuscript with Paid Access

Authors who publish with this journal agree to the following terms:
    1. Publisher retain copyright .

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .